A Comparative Study of Maternal Serum Stathmin-1 Levels in Pregnancies With Preeclampsia, Severe Preeclampsia, and Healthy Controls
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 84
- 试验地点
- 1
- 主要终点
- Maternal Serum Stathmin-1
研究概览
简要总结
This study investigates maternal serum Stathmin-1 (STMN-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology. Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Clinical diagnosis of Preeclampsia: Defined by New-onset hypertension (Systolic Blood Pressure ≥140 mmHg and/or Diastolic Blood Pressure ≥90 mmHg) after 20 weeks of gestation, with or without proteinuria.
- •Clinical diagnosis of Severe Preeclampsia: Defined by criteria such as severe hypertension (systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg), organ dysfunction (renal insufficiency, liver involvement, neurological complications), thrombocytopenia, pulmonary edema, or fetal growth restriction.
- •Control Group: Healthy pregnancies without preeclampsia
排除标准
- •Multiple Pregnancies
- •Pregestational Diabetes
- •Chronic Hypertension
- •Systemic Diseases (Chronic kidney disease, autoimmune diseases)
- •Fetal Anomalies
- •Premature Rupture of Membranes
结局指标
主要结局
Maternal Serum Stathmin-1
时间窗: Up to 8 weeks (Patients will be followed from inclusion in the study until the end of their pregnancy.)
To compare Stathmin-1 Levels between the pre-eclampsia and the control group.
次要结局
未报告次要终点
研究者
Gökhan Bolluk
MD
Başakşehir Çam & Sakura City Hospital